Skip to main content
. Author manuscript; available in PMC: 2008 Oct 31.
Published in final edited form as: Int Arch Allergy Immunol. 2007 Oct 4;145(3):231–243. doi: 10.1159/000109292

Fig. 6.

Fig. 6

PC61 treatment prior to OVA-alum sensitization results in increased eosinophilia at AAD and LIT. Mice were treated with either control antibody (Rat IgG; □) or CD25+ T cell-depleting antibody (PC61; ▧) at the indicated time points and then subjected to OVA sensitization and aerosol challenge. a PC61 treatment on day 21 of continuous aerosol exposure, sacrifice on day 42 (LIT). b PC61 treatment prior to sensitization, sacrifice on day 3 (3-day AAD). c PC61 treatment prior to sensitization, sacrifice on day 42 (LIT). Mice were sacrificed, and BAL fluid was collected and analyzed via differential cell counts for the presence of macrophages (MAC), neutrophils (PMN), lymphocytes (LYMPH) and eosinophils (EOS). Data represent the mean ± SEM. * p < 0.05 vs. all groups. Four to five mice were used in all groups. ■ = Control.